Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 3/20 | 0.84 |
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.59 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11918074 | 0.92 | DDX3X (1.00) | DDX3XRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL1659299 | 0.92 | DDX3X (1.00) | DDX3XRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL27568751 | 0.87 | DDX3X (0.73) | DDX3XRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL4416620 | 0.86 | SMN1; SMN2 (0.77) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL29703055 | 0.86 | SMN1; SMN2 (0.77) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL812756 | 0.84 | DDX3X (0.80) | DDX3XRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL259602 | 0.84 | SMN1; SMN2 (0.75) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL31054278 | 0.84 | SMN1; SMN2 (0.75) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL17079603 | 0.84 | DDX3X (0.79) | DDX3XRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL17079631 | 0.84 | DDX3X (0.79) | DDX3XRAB9ANPC1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | DDX3X 1700/4885RAB9A 3470/4885NPC1 2173/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | DDX3X 445/4885RAB9A 3241/4885NPC1 48/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | DDX3X 631/4885RAB9A 3975/4885NPC1 297/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | DDX3X 420/4885RAB9A 2829/4885NPC1 87/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | DDX3X 420/4885RAB9A 2829/4885NPC1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.